Allergy Therapeutics PLC Stock
€0.13
Your prediction
Allergy Therapeutics PLC Stock
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
Cons
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | 0.780% | 0.781% | 13.158% | 61.250% | 10.256% | 171.579% | -35.013% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 0.000% | 2.128% | 11.628% | 7.143% | -11.111% | -55.963% |
| Eledon Pharmaceuticals Inc. | -8.280% | 4.348% | -2.703% | -64.706% | 12.500% | -43.750% | -87.911% |
| SELLAS Life Sciences Group Inc | -10.530% | -19.189% | 73.233% | 221.505% | 5.467% | 16.297% | -42.099% |
News
3 of the Best Stocks Under $100 to Buy in 2026
Want some good, cheap stocks to buy for the new year? The ones that I've listed below all trade below $100 a share, are cheap with respect to their earnings, and offer a mix of value, dividends, and
Datavault AI and The Dream Bowl to Set New Benchmark in Sports Innovation with World’s First Tokenized Autograph Session, Featuring Current and Future NFL Stars - Live on ESPN+
30 former NFL star players from different NFL Teams will autograph on-site up to 3,000 The Dream Bowl memorabilia items such as helmets, footballs, jerseys, and live-autographs by Notable
Can ASTS Stock Beat the Market in 2026?
AST SpaceMobile (NASDAQ: ASTS) was a bad investment from 2020 to the start of 2024. The stock woefully underperformed the S&P 500 during that stretch and went from $20 per share to $2 per share


